Related Experiment Video
Updated: Mar 31, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease
Daichi Fujimoto1, Ryoko Shimizu2, Ryoji Kato2
1Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan daichianzen@yahoo.co.jp.
Background:
The safety and efficacy of second-line chemotherapy for treating patients with small cell lung cancer (SCLC) and interstitial lung disease (ILD) have not been elucidated to date.
Patients And Methods:
Between January 2005 and September 2013, we analyzed 23 patients with SCLC and ILD who received second-line chemotherapy. Pre-existing ILD was diagnosed according to clinical features and pretreatment chest high-resolution computed tomography results.
Results:
The overall objective response rates and disease control rates were 22% and 52%, respectively. The median respective durations of progression-free survival and overall survival were 2.1 months (95% confidence interval (CI)=2.0-3.0 months) and 7.1 months (95% CI=3.6-11.3 months), respectively. Three patients with unusual interstitial pneumonia pattern (13%) developed chemotherapy-related pneumonitis.
Conclusion:
Second-line treatment may be an effective and safe option for SCLC patients with ILD after sufficient evaluation of risks and benefits.
